Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome

Joseph A. Lewnard (), Vennis Hong, Jeniffer S. Kim, Sally F. Shaw, Bruno Lewin, Harpreet Takhar and Sara Y. Tartof ()
Additional contact information
Joseph A. Lewnard: University of California, Berkeley
Vennis Hong: Kaiser Permanente Southern California
Jeniffer S. Kim: Kaiser Permanente Southern California
Sally F. Shaw: Kaiser Permanente Southern California
Bruno Lewin: Kaiser Permanente Southern California
Harpreet Takhar: Kaiser Permanente Southern California
Sara Y. Tartof: Kaiser Permanente Southern California

Nature Communications, 2023, vol. 14, issue 1, 1-11

Abstract: Abstract Expansion of the SARS-CoV-2 BA.4 and BA.5 Omicron subvariants in populations with prevalent immunity from prior infection and vaccination, and associated burden of severe COVID-19, has raised concerns about epidemiologic characteristics of these lineages including their association with immune escape or severe clinical outcomes. Here we show that BA.4/BA.5 cases in a large US healthcare system had at least 55% (95% confidence interval: 43–69%) higher adjusted odds of prior documented infection than time-matched BA.2 cases, as well as 15% (9–21%) and 38% (27–49%) higher adjusted odds of having received 3 and ≥4 COVID-19 vaccine doses, respectively. However, after adjusting for differences in epidemiologic characteristics among cases with each lineage, BA.4/BA.5 infection was not associated with differential risk of emergency department presentation, hospital admission, or intensive care unit admission following an initial outpatient diagnosis. This finding held in sensitivity analyses correcting for potential exposure misclassification resulting from unascertained prior infections. Our results demonstrate that the reduced severity associated with prior (BA.1 and BA.2) Omicron lineages, relative to the Delta variant, has persisted with BA.4/BA.5, despite the association of BA.4/BA.5 with increased risk of breakthrough infection among previously vaccinated or infected individuals.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-023-37051-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37051-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-37051-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().